Hepatic 31P magnetic resonance spectroscopy: A hepatologist's user guide

Liver International

Volumn 25, Issue 3, 2005, Pages 490-500

  Solga, Steven F ^a,c   Horska, Alena ^a   Clark, Jeanne M ^a   Diehl, Anna Mae ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DUKE UNIVERSITY   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Liver; Phosphorus magnetic resonance spectroscopy

Indexed keywords

ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; ALANINE; CREATINE PHOSPHATE; GLUCOSE 6 PHOSPHATE; PHOSPHATE; PHOSPHODIESTERASE; PHOSPHOETHANOLAMINE; PHOSPHORUS 31; PHOSPHORYLCHOLINE; DIAGNOSTIC AGENT; PHOSPHORUS;

ALCOHOL LIVER CIRRHOSIS; ANALYSIS OF VARIANCE; BIOCHEMISTRY; CELLULAR DISTRIBUTION; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEASIBILITY STUDY; HELLP SYNDROME; HEPATITIS A; HUMAN; IN VIVO STUDY; INFORMATION PROCESSING; LIVER CANCER; LIVER METABOLISM; LIVER METASTASIS; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDICAL SPECIALIST; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRACTICE GUIDELINE; PROTEIN LOCALIZATION; REVIEW; SIGNAL DETECTION; GASTROENTEROLOGY; INSTRUMENTATION; LIVER DISEASE; METHODOLOGY;

GASTROENTEROLOGY; HUMANS; LIVER DISEASES; MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHORUS ISOTOPES;

EID: 20844461356     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01131.x     Document Type: Review

References (46)

1. Oberhaensli R D, Galloway G J, Taylor D J, Bore P J, Radda G K. Assessment of human liver metabolism by phosphorus-31 magnetic resonance spectroscopy. Br J Radiol 1986; 59: 695-9.
2. Dobbins R L, Malloy C R. Measuring in-vivo metabolism using nuclear magnetic resonance. Curr Opin Clin Nutr Metab Care 2003; 6(5): 501-9.
3. Szczepaniak L S, Nurenberg P, Leonard D, Browning J D, Reingold J S, Grundy S, Hobbs H H, Dobbins R L. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288(2): E462-8. Epub 2004 Aug 31.
4. Roden M, Petersen K F, Shulman G I. Nuclear magnetic resonance studies of hepatic glucose metabolism in humans. Recent Prog Horm Res 2001; 56: 219-37.
5. Klomp D W, Van Laarhoven H W, Kentgens A P, Heerschap A. Optimization of localized 19F magnetic resonance spectroscopy for the detection of fluorinated drugs in the human liver. Magn Reson Med 2003; 50(2): 303-8.
6. 1H-NMR investigation in vitro of normal and abnormal human liver. Biochim Biophys Acta 1993; 1225: 71-7.
7. 31P nuclear magnetic resonance study. Biochim Biophys Acta 1995; 1272: 113-8.
8. Sherlock S, Dooley J. Diseases of the Liver and Biliary System, 11th edn. Oxford: Blackwell Science Ltd., 2002; 8.
9. Canioni P, Quistorff B. Liver physiology and metabolism in NMR in Physiology and Biomedicine. New York: Academic Press Inc., 1994; 373.
10. Canioni P, Quistorff B. Liver Physiology and Metabolism in NMR in Physiology and Biomedicine. New York: Academic Press Inc., 1994; 373-88.
11. Menon D K, Sarentoni J, Taylor-Robinson S D, Bell J D, Cox I J, Bryant D J, et al. Effect of functional grade and etiology on in vivo hepatic phosphorus-31 magnetic resonance spectroscopy in cirrhosis: biochemical basis of spectral appearances. Hepatology 1995; 21(2): 417-27.
12. 31P MRS in vivo: part II: Muscle, Liver, Kidney. Magn Reson Med 1994; 32: 453-8.
13. 31P NMR spectroscopy. J Biol Chem 1987; 262(31): 14875-8.
14. 31P signal. Magn Reson Med 1989; 12: 145-50.
15. 31P nuclear magnetic resonance spectroscopic investigation of human neuroblastoma in situ. N Engl J Med 1985; 312: 1500-5.
16. Cox I J, Menon D K, Sargentoni J, Bryant D J, Collins A G, Coutts G A, et al. Phosphorus-31 magnetic resonance spectroscopy of the human liver using chemical shift imaging techniques. J Hepatol 1992; 14: 265-75.
17. 31P NMR spectra in vivo. Magn Reson Med 1989; 12: 282-9.
18. 1 values of phosphorus metabolites in human liver and muscle determined at 1.5 T by chemical shift imaging. NMR Biomed 1989; 2(5/6): 298-304.
19. Gallis J L, Delmas-Beauvieux M C, Biran M, Rousse N, Durand T, Canioni P. Is cellular integrity responsible for the partial NMR invisibility of ATP in isolated ischemic rat liver. NMR Biomed 1991; 4: 279-85.
20. 31P NMR visibility of ATP in the perfused rat liver remains about 90% unaffected by changes in the metabolic state. Biochemistry 1992; 31: 7488-93.
21. 31P NMR of iosolated perfused mouse liver: effects of valinomycin and nigericin. In: Society of Magnetic Resonance in Medicine, 11th Annual Meeting, Berlin, Book of Abstracts, 1992; Vol 1; 486.
22. 31P Magnetic Resonance. J Biol Chem 1973; 248(20): 7276-8.
23. 31P magnetic resonance spectroscopic studies of the hepatic response of healthy rats and rats with acute hepatic damage to fructose loading. Magn Reson Med 1994; 31: 469-81.
24. 31P magnetic resonance spectroscopy. NMR Biomed 1990; 3: 17-22.
25. 31P MR spectroscopy assessed liver metabolic concentrations from different institutions. MR Imaging 1998; 16(2): 205-11.
26. 31P NMR study of the phosphorylated metabolites compartmentation, intracellular pH and phosphorylation state during normoxia, hypoxia, and ethanol perfusion. Eur J Biochem 1987; 162: 151-9.
27. 31P MRS in vivo: part II: Muscle, Liver, Kidney. Magn Reson Med 1994; 32: 453-8.
28. 31P-magnetic resonance spectroscopy for early graft function. Transplantation 1997; 64(1): 147-52.
29. 31P NMR spectra. Magn Reson Med 1994; 32: 801-3.
30. 31P chemical shift imaging of the human liver. Magn Reson Imaging 1995; 13(4): 621-8.
31. Cox I J, Menon D K, Sargentoni J, Bryant D J, Collins A G, Coutts G A, et al. Phosphorus-31 magnetic resonance spectroscopy of the human liver using chemical shift imaging techniques. J Hepatol 1992; 14: 265-75.
32. 31P MR spectroscopy assessed liver metabolic concentrations from different institutions. MR Imaging 1998; 16(2): 205-11.
33. 31P MRS. NMR Biomed 2003; 16(3): 168-76.
34. 1H MRI at 1.5 and 2.0 T. Magn Reson Med 1990; 13(2): 228-38.
35. 31P MRS study. Br J Cancer 1993; 67(5): 1145-53.
36. 31P MRS spectroscopy of benign and malignant breast tumors. Korean J Radiol 2001; 2(2): 80-6.
37. Podo F. Tumour phospholipid metabolism. NMR Biomed 1999; 12(7): 413-39.
38. 31P-magnetic resonance spectroscopy. Metabolism 2000; 49(10): 1335-9.
39. 31P magnetic resonance spectroscopic studies of the hepatic response of healthy rats and rats with acute hepatic damage to fructose loading. Magn Reson Med. 1994; 31(5): 469-81.
40. 31P magnetic resonance spectroscopy. Biochimie 1991; 73(1): 105-8.
41. 31P MRS study in pig liver. J Hepatol 1997; 26(2): 336-42.
42. Changani K K, Fuller B J, Bell J D, Taylor-Robinson S D, Moore D P, Davidson B R. Improved preservation solutions for organ storage: a dynamic study of hepatic metabolism. Transplantation 1999; 68(3): 345-55.
43. Mann D V, Lam W W, Hjelm N M, So N M, Yeung D K, Metreweli C, Lau W Y. Metabolic control patterns in acute phase and regenerating human liver determined in vivo by 31-phosphorus magnetic resonance spectroscopy. Ann Surg 2002; 235(3): 408-16.
44. Leij-Halfwerk S, van den Berg J W, Sijens P E, Wilson J H, Oudkerk M, Dagnelie P C. Altered hepatic gluconeogenesis during L-alanine infusion in weight-losing lung cancer patients as observed by phosphorus magnetic resonance spectroscopy and turnover measurements. Cancer Res 2000; 60(3): 618-23.
45. Agteresch H J, Leij-Halfwerk S, van den Berg J W, Hordijk-Luijk C H, Wilson J H, Dagnelie P C. Effects of ATP infusion on glucose turnover and gluconeogenesis in patients with advanced non-small-cell lung cancer. Clin Sci (London) 2000; 98(6): 689-95.
46. 31P magnetic resonance spectroscopy study. Hepatology 2002; 35(2): 421-4.